Sign In
Buy MRK
$120.78
+1.69 (+1.41%)
At Close: Jun 11, 2026
Merck Stock Looks Undervalued as KEYTRUDA Growth and Pipeline Offset Near-Term Headwinds
01:17pm, Tuesday, 05'th May 2026
Merck (NYSE:MRK | MRK Price Prediction) delivered its fourth consecutive earnings beat, but shares slipped on the earnings report.
Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
08:45am, Tuesday, 05'th May 2026
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the acquisition of Terns Pharmaceuticals, Inc. (“
3 Monster Dividend Stocks That Could Pay You Through the Next Decade of Chaos
05:15am, Tuesday, 05'th May 2026
It's time to start thinking at least a little bit defensively by exchanging long-term potential gains for certain near-term cash flow.
Merck (MRK) Price Forecast: Double Top Signals Deeper Correction Risk
04:56pm, Monday, 04'th May 2026
Merck stock shows a confirmed double top breakdown, signaling potential downside risk, while key moving averages and resistance zones now shape the outlook for a deeper correction.
Warren Buffett Owns 2 of the Small Dogs of the Dow: Here's Why You Need to Own All 5
07:44am, Monday, 04'th May 2026
The “Dogs of the Dow” is a well-known strategy first published in 1991 by Michael O'Higgins.
Merck: 'Strong Buy' - Terns Acquisition And Ability To Counter Keytruda Patent Loss
09:35am, Sunday, 03'rd May 2026
Merck retains a 'strong buy' rating, driven by proactive oncology pipeline expansion to offset KEYTRUDA patent expiration in 2028. Acquisition of Terns Pharmaceuticals brings TERN-701, a best-in-disea
Merck's LOE Risks Mitigated - R&D And M&As Are Paying Off
09:49am, Saturday, 02'nd May 2026
Merck once again suffers the mixed optics from the updated FY2026 adjusted EPS guidance, attributed to the IPR&D charges related to two recent acquisitions. Their in-house capabilities remain excellen
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (May 2026)
08:00am, Saturday, 02'nd May 2026
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter
Merck & Co., Inc. (MRK) Q1 2026 Earnings Call Transcript
04:41pm, Thursday, 30'th Apr 2026
Merck & Co., Inc. (MRK) Q1 2026 Earnings Call Transcript
MRK Q1 Earnings & Sales Beat Estimates, 2026 Sales View Tightened
03:46pm, Thursday, 30'th Apr 2026
Merck tops Q1 estimates as Keytruda drives growth and lifts 2026 EPS outlook despite acquisition charge. Sales view tightened.
Merck Sales Beat As Winrevair Hits $525 Million
02:03pm, Thursday, 30'th Apr 2026
Merck and Co. (MRK) delivered a first-quarter sales beat that could help calm investor concerns around one of the most important transition periods in the company
Merck (MRK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
10:36am, Thursday, 30'th Apr 2026
Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street est
S&P 500 Rides Tech Earnings Wave Despite Inflation Warning Shot
09:09am, Thursday, 30'th Apr 2026
The S&P 500 (^GSPC) is off to the races this morning, up 0.50% thanks to tailwinds from mega-cap earnings beats and a sharp pullback in oil prices, even as the Fed's preferred inflation gauge ran hott
Merck (MRK) Reports Q1 Loss, Tops Revenue Estimates
08:41am, Thursday, 30'th Apr 2026
Merck (MRK) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.51. This compares to earnings of $2.22 per share a year ago.
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
08:05am, Thursday, 30'th Apr 2026
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NC
